Story preview
Continue reading on the publisher site for the full article.
Read on publisher →AD HOC NEWS
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Context from Wikipedia on the organisations, people and places in this story.
American multinational biotechnology company
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl…
More on Wikipedia ↗Outlets covering it
3
in the last 3 days
First reported
41 hr. ago
1 outlets since
Countries
2 other outlets reported this story in the last 3 days.
Biogen stock costs EUR 199.33 on October 6, 2026 after EUR 197.76. Litifilimab reached 27.20 percent
Biogen reported 52 week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, with sustained skin disease activity improvements and a generally well tolerated safety profile across 93 adults who had limited benefit from standard antimalarials. The litifilimab data extends to a full…